ORS 475A.200
Legislative findings
(1)
Oregon has the one of the highest prevalence of mental illness among adults in the nation;(2)
An estimated one in every five adults in Oregon is coping with a mental health condition;(3)
The Governor has declared addiction as a public health crisis in this state;(4)
The 2019-2021 Governor’s Budget proposes spending over $2.8 billion on mental health and behavioral health programs;(5)
Studies conducted by nationally and internationally recognized medical institutions indicate that psilocybin has shown efficacy, tolerability, and safety in the treatment of a variety of mental health conditions, including but not limited to addiction, depression, anxiety disorders, and end-of-life psychological distress;(6)
The United States Food and Drug Administration has:(a)
Determined that preliminary clinical evidence indicates that psilocybin may demonstrate substantial improvement over available therapies for treatment-resistant depression; and(b)
Granted a Breakthrough Therapy designation for a treatment that uses psilocybin as a therapy for such depression;(7)
The Oregon Health Authority has direct supervision of all matters relating to the preservation of life and health of the people of this state;(8)
During a two-year program development period, the authority should:(a)
Examine, publish, and distribute to the public available medical, psychological, and scientific studies, research, and other information relating to the safety and efficacy of psilocybin in treating mental health conditions; and(b)
Adopt rules and regulations for the eventual implementation of a comprehensive regulatory framework that will allow persons 21 years of age and older in this state to be provided psilocybin services; and(9)
An advisory board should be established within the authority for the purpose of advising and making recommendations to the authority. [2021 c.1 §1]
Source:
Section 475A.200 — Legislative findings, https://www.oregonlegislature.gov/bills_laws/ors/ors475A.html.
Up to date